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HIV-1’s subtype C V3 loop consensus sequence exhibits increased resistance to anti-V3 antibody-mediated neutralization as
compared to the subtype B consensus sequence. The dynamic 3D structure of the consensus C V3 loop crown, visualized by
ab initio folding, suggested that the resistance derives from structural rigidity and non-β-strand secondary protein structure in
the N-terminal strand of the β-hairpin of the V3 loop crown, which is where most known anti-V3 loop antibodies bind. The
observation of either rigidity or non-β-strand structure in this region correlated with observed resistance to antibody-mediated
neutralization in a series of chimeric pseudovirus (psV) mutants. The results suggest the presence of an epitope-independent,
neutralization-relevant structural diﬀerence in the antibody-targeted region of the V3 loop crown between subtype C and subtype
B, a diﬀerence that we hypothesize may contribute to the divergent pattern of global spread between these subtypes. As antibodies
to a variable loop were recently identiﬁed as an inverse correlate of risk for HIV infection, the structure-function relationships
discussed in this study may have relevance to HIV vaccine research.
1.Introduction
Subtype C infections now represent the majority of HIV-1
infections worldwide [1], suggesting greater in vivo or host-
pathogen ﬁtness. By contrast, in direct in vitro competition
assays, R5 subtype B isolates outcompete R5 subtype C iso-
lates [2], suggesting greater in vitro infective ﬁtness. Thus,
more rapid in vivo spread of subtype C infections may be
occurring despite an apparent greater in vitro ﬁtness of sub-
type B.
Diﬀerential susceptibility to human antibody-mediated
neutralization could result in diﬀering extents of global
spread between diﬀerent subtypes. The V3 loop is often
referred to as the principal neutralizing determinant of HIV-
1 viruses as several of the early and recent studies describing
human antibodies that could neutralize HIV-1 were dom-
inated by anti-V3 loop antibodies [3–6]. Indeed, several
observations suggest a conformational or functional diﬀer-
ence between subtype B and subtype C V3 loops [7], but the
nature of the diﬀerence has not been elucidated. The V3 loop
is also the site of CCR5 and CXCR4 engagement, a necessary
determinant of virus entry [8–13]. Thus, antibody neutral-
ization determinants and infective determinants coincide
to the same location on the HIV-1 envelope glycoprotein
surface, and disturbances to one are likely to aﬀect the other.
A comparison of antibody-mediated neutralizations of
SF162 chimeric psVs carrying the consensus subtype C V3
loop sequence (conC) to those for the consensus subtype B
V3 loop sequence (conB) by two diﬀerent broadly neutraliz-
ing anti-V3 loop monoclonal antibodies (mAbs) previously
demonstrated that ConC has substantially more resistance to
neutralization mediated by both antibodies (Figure 1)[ 14].
Each of those mAbs (i.e., 2219 and 447-52D) has been crys-
tallographically conﬁrmed to have distinct V3 loop binding
modes [15, 16]. Poorly characterized and variable V3 loop
surface exposure features were controlled in these experi-
ments using a previously established approach in which psVs
are constructed to express diﬀerent sequences of the V3 loop
within the same SF162 Env background [17]. SF162 is sensi-
tive to antibody-mediated neutralization and in this setting2 Advances in Virology
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Figure 1: Neutralization of chimeric psVs by antibodies 447-52D
(purple) and 2219 (blue). The psV consist of the SF162 strain with
its V3 loop replaced by the indicated V3 loop sequence. Consensus
B-R18Q is a psV consisting of the consensus subtype B V3 loop
sequence with position 18 in the V3 loop mutated from a subtype
B consensus arginine to a subtype C consensus glutamine. IC50 is
the amount of antibody in ug/mL required to achieve 50% neutral-
ization. The negative base 10 logarithm of the IC50 has been plotted
for easier comparison: higher, positive bars towards the top of the
graph indicate strong neutralization by the antibody. Antibodies
were only tested to a concentration of 20ug/mL for neutralization,
so the negative value of 1.3 on the plot is maximal and indicated no
detectable neutralization by the antibody. Adapted from [14].
provides a relatively constant level of V3 loop exposure and
a minimal Env variability background across the diﬀerent
chimeric psVs. Diﬀerences in neutralization between two
mutants diﬀering only in their V3 loop sequences should
therefore be caused by structural diﬀerences in the V3 loop
itself. Thus, some portion of the subtype C virus resistance
to anti-V3 antibody-mediated neutralization maps to the V3
loop itself and not to structural eﬀects outside the V3 loop
or to surface exposure diﬀerences between subtype B and
subtype C.
Previous analysis of the 3D interaction surface of 2219
and 447-52D bound to the V3 loop divides the V3 loop into
amino acid positions that comprise the Ab “epitope” and
thosethatdonot[14].The3DstructureoftheepitopeorAb-
bound surface can be divided into two functionally distinct
categories. The ﬁrst category is amino acids that were found
to comprise the neutralization epitope: these are deﬁned
as tight (usually electrostatic), substitution-intolerant com-
plementarities between pockets on the antibody surface,
and speciﬁc V3 amino acid side chains that restrict the
neutralization activity of the antibody. These amino acids
were identiﬁed as R18 for 447-52D and K10-I12-Y21 for
antibody 2219 [14], where the number following each amino
acid single-letter designation refers to the position of that
amino acid in the V3 loop starting with the disulﬁde-bonded
cysteine as number 1. Mutation of any of these amino acid
side chains disrupt Ab-mediated neutralization strongly.
The second category is the rest of the epitope or Ab-
bound 3D molecular surface: mutation-tolerant contacts
between loosely bound V3 side chains or the V3 loop back-
bone and the antibody binding surface that depend on the
overall tertiary shape of the bound V3 loop conformation.
We deﬁne these areas as mutation insensitive, “epitope-inde-
pendent” locations for the purposes of this study, although
technically all atoms contacting the Ab comprise the epitope
and these locations can indirectly inﬂuence the epitope.
The conC sequence diﬀers from the conB sequence in the
former, substitution-intolerant type of contact. Thus, with
a Q18 present in ConC versus R18 in ConB, the chimeric
psV carrying the conC loop was shown to be predictably
resistant to antibody 447-52D (up to 20ug/mL tested, Figure
1). However, when this important contact was abolished
in the conB sequence (by an R-to-Q mutation at position
18 (R18Q), antibody-mediated neutralization was reduced
but not abolished, indicating that the observed resistance
to antibody-mediated neutralization does not depend com-
pletely on this speciﬁc neutralization epitope contact (Figure
1). Conversely, the conC sequence does not diﬀer from the
conB sequence in neutralization epitope contacts for anti-
body 2219 (K10, I12, and Y21), but conB is sensitive to 2219
antibody-mediated neutralization while conC is partially
resistant. The magnitude of this epitope-independent resist-
ance for 2219 is approximately of the same magnitude as that
inferredfor447-52D.Thus,forbothantibodies,asubstantial
epitope-independent structural mechanism, present in conC
but not in conB, appears to underlie resistance to anti-V3
antibody-mediated neutralization of the subtype C virus.
We therefore hypothesized that we could visualize the
3D structural basis of the epitope-independent diﬀerential
resistance observed between the subtype B and subtype C V3
loops by correlating previously published psV neutralization
measurements with dynamic 3D structural visualization of
several carefully constructed V3 loop mutants. In order to do
this, we needed a minimum of 2 Abs with crystallographical-
ly conﬁrmed diﬀerences in their targeted V3 crown epitopes,
so Abs 447-52D and 2219 were chosen, but we expect these
results to apply generally to all V3 crown-targeted Abs.
2. Results
2.1. The Segment at Positions 12 to 14 of the Consensus C
V3 Loop Crown Has a Rigid, Non-β-Strand Conformation.
Several recent studies have visualized snapshots of the 3D
structure of the V3 loop by NMR and crystallography [15,
16, 25]. One common feature of mAbs 2219 and 447-52D
is that both bind positions 12 to 14 of the V3 loop in an
antiparallel β-sheet fashion. This result may be applicable to
most broadly neutralizing anti-V3-loop antibodies, as their
linear epitopes overlap, for the most part, at the N-terminal
β-strand (positions 12 to 14) of the V3 loop (M. Gorny,
personal communication). The β-strand at positions 12–14
of the V3 loop appears to be a common structural feature
required for recognition and function of anti-V3 antibodies.
Since this region makes mostly backbone (non-side-chain)
contacts with the V3 antibodies, the protein backbone
conformation of this region (i.e., α-helical, β-strand, etc.) is
likelytoinﬂuenceanti-V3antibody-mediatedneutralization.Advances in Virology 3
We therefore examined this region carefully for backbone
conformational diﬀerences between neutralization-resistant
conC and neutralization-sensitive conB. ab initio peptide
folding algorithms have previously been shown to be capable
of predicting the ﬂexibility and conformational preferences
of the V3 loop crown, recapitulating crystallographic forms
(See Supplementary Figure 1 in the Supplementary Material
available online at doi:10.1155/2012/803535) and demon-
strating that the V3 loop crown from positions 10 to 22
of the V3 loop behaves as an autonomously folded, but
ﬂexible, domain [18–20]. Folding a peptide identical in
sequence to the conC V3 crown from positions 10 to 22
shows that the peptide backbone prefers a rigid, non-β-
strand structure at positions 12 to 14 (Figure 2). In contrast,
a peptide identical in sequence to amino acids 10–22 of the
conB V3 crown backbone adopts a ﬂexible conformation
withclearβ-strandcharacteratpositions12to14andoverall
ac l e a rβ-hairpin fold (Figure 2). The key positions in the
conB sequence consistently adopt φ-ϕ angles typical of a
Type II beta-hairpin at the V3 GPG sequence, while these
are lost in conC. The rigidity and non-β-strand structure
of the 12–14 V3 segment in the subtype C V3 crown may
presentanenergeticbarriertopeptidedeformationsrequired
for antibody-mediated neutralization, speciﬁcally bending
of the structure into and out of a neutralization relevant
β-strand conformation. Thus, these results suggest the fol-
lowing epitope-independent structure-activity relationship:
anti-V3-loop-antibody-mediated neutralization depends on
aﬂ e x i b l eβ-strand at positions 12 to 14 in the V3 loop.
2.2. Substitutions in the V3 Antibody Binding Site Aﬀect the
Rigidity and β-Strand Conformation of This Area. We began
by focusing on the structural eﬀects of mutations at the
key positions 13 and 14 of the subtype C V3 loop by
folding a series of V3 loop crowns with point mutations at
these positions (Table 1). Position 12 was avoided because
it is part of the neutralization epitope for 2219 and such
mutants would therefore obviate a standardized assessment
of the non-epitope-dependent eﬀects across mutants. ab
initio folding of conC mutated in the 14th position of
the V3 loop from Ile to Met (I14M) mildly increased the
ﬂexibility of the V3 crown but retained a strong β-hairpin
conformation. ab initio folding of an I14V conC mutant
restored full ﬂexibility and 2/3 β-strand character to this
local region. Folding of I14L demonstrated a non-β strand,
partly α-helical conformation. Interestingly, we previously
demonstrated that α-helical conformations in this region are
suﬃciently disruptive to abolish infectivity of the virus [20],
suggestingthatI14Lhasthestrongestresistancetoantibodies
in this dataset but may also be the least infective construct.
I14F re-established two-thirds of the β-strand in the 12 to
14 region, but did not preserve a β-hairpin as the C-terminal
strandoftheV3crowndidnotcontacttheN-terminalstrand
and the overall structure remained somewhat rigid.
Comparison of this folding data with neutralization
data from in vitro chimeric psVs with the same mutations
showed that loss of 2219 antibody-mediated neutralization
correlated with the loss of both β-strand character and
Table 1: antibody-mediated neutralization of psVs constructed
from SF162 with the V3 loop replaced by the consensus C or
consensusBV3loopsequencewithand withouttheindicated point
mutations in the “Sequence” column. In vitro measured strong,
weak, or no neutralization is indicated along with the IC50 (ug/mL)
inthe“Neutralization”columnontheright.Numberingofmutated
residues is from the beginning of the V3 loop with the starting
cysteinebeingresiduenumber1sothatD25E(V3loopnumbering)
is the same as D322E (numbering of residues from N-terminus of
gp120). The “Flex” column is the structural ﬂexibility of the V3
crown from positions 10 to 22 as assessed by ab initio folding: +++
indicates no energy gap and many conformations near the energy
minimum suggesting a ﬂexible structure; ++, +, and −indicate a
spectrum of energy gaps of <2 U slightly more than the standard
error of the energy function suggesting a partly ﬂexible structure;
−− indicates an energy gap >2 U indicating a rigid conformation.
The “β-hairpin” column is the β-strand character of positions 12
to 14 as assessed in the same ab initio folding: +++ indicates that
all three residues from 12 to 14 adopt canonical β-strand φ and
Ψ angles in the lowest energy structure; ++ indicates that two of
the three residues from 12 to 14 adopt canonical β-strand φ and
Ψ angles; + indicates that two or more of the residues from 12 to
14 adopt canonical β-strand φ and Ψ angles, but that the overall
structuredoesnotformaβ-hairpin.–and −−indicatethatresidues
from 12 to 14 adopt canonical non-β-strand φ and Ψ angles.
Sequence Flexibility β-Hairpin Naturalization
(IC50 μg/mL)
Consensus B +++ +++ Strong (0.001)
B-R18Q +++ +++ Strong (0.001)
B-T22A +++ ++ Strong (0.002)
C-I14V ++ +++ Strong (0.01)
C-T19A + +++ Weak (0.02)
C-I14M ++ −− Weak (0.03)
C-I14F − ++ Weak (0.1)
Consensus C −− −− None (0.15)
C-D25E −− −− None (0.15)
C-I14L −− − None (0.15)
structural ﬂexibility, while reduction of 2219 neutralization
is associated with the loss of either factor independently
(Table 1). As noted previously, all tested chimeric psVs from
Table 1 preserve thekey 2219 binding epitope side chains asa
control feature, so increased resistance to antibody-mediated
neutralization appears to correlate with loss of β-strand or β-
hairpinconformationintheV3loopand/orlossofstructural
ﬂexibility at positions 12 to 14 in an epitope-independent
manner.
Mutations anywhere in the V3 crown can aﬀect the
folding of the whole crown, and as such simulations were
performed for mutations outside of positions 13 and 14.
In silico mutations at positions 18 and 22 in conB did not
alter the folding signiﬁcantly (Table 1). A conC T19A in
silico mutation did alter overall folding somewhat, resulting
in partial restoration of ﬂexibility and full restoration of β-
strand character at 12–14. These results also correlated with
the previously noted resistance of in vitro chimeric psVs to
2219 antibody-mediated neutralization, so changes outside
the key Ab-targeted region can indirectly aﬀect folding, and4 Advances in Virology
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Figure 2: (a) Top: lowest energy conformation of the subtype C V3 loop crown from V3 loop amino acid positions 10 to 22. The structure
is shown in ribbon representation colored in a gradient from the N-terminal residue at position 10 (dark blue) to the C-terminal residue
at position 22 (colored dark red). The side chain conformations of Ile12, Arg13, and Ile14 are shown in full-atom wire representation.
Their backbone curvature and fanned orientation are inconsistent with β-strand secondary structure. Bottom: plot of 180 lowest energy
conformations from the folding simulation. x-axis (ENER): energy score ranging from lowest at the left to higher at the right. y-axis (NVIS):
number of visits by the simulation to the indicated conformation. For example, the lowest energy conformation was found again and again
by the search over 150 times. The presence of a 4kcal simulation energy unit gap in the subtype C simulation indicates a rigid structure
as a 4kcal energy barrier prevents exit from the lowest energy conformation most of the time on the biological time scale. (b) Top: lowest
energy conformation of the subtype B V3 loop crown from positions 10–22 depicted as in A. The extended linear conformation of Ile12,
Arg13, and Ile14 with alternating directions for the side chains is typical of canonical β-strand structure. Bottom: plot of 180 lowest energy
conformations from the folding simulation as in A. Many conformations are present near the lowest energy conformation in this subtype B
simulation predicting a ﬂexible structure that ﬂickers between ∼10 conformations all the time (is ﬂexible) on the biological timescale.
the observed eﬀect is tertiary and not speciﬁcally dependent
on any amino acid position.
2.3. The Epitope-Independent Eﬀect May Be General to a
Wide Variety of Anti-V3 Antibodies. When tested with 14
broadly neutralizing anti-V3 antibodies derived from donors
infected with subtypes A and B, the conC chimeric psV
was neutralization resistant to all of the mAbs to a much
greater degree than the conB chimeric psV (Table 2). A
non-V3 Ab—b12—did not show the same magnitude of
eﬀect. In the panel, 447-52D and 2219 are known to have
distinct epitopes, and it is likely that many of the other mAbs
have distinct epitopes as well. The common resistance of
conC to all these diﬀerent antibodies suggests an epitope-
independent structural resistance to neutralization residing
in the V3 loop.
3. Discussion
The experimental results described here indicate that a sig-
niﬁcant fraction of the anti-V3 antibody-mediated neutral-
ization resistance of the conC sequence maps directly to the
antibody-bindingdomainoftheV3crown.Furthermore,the
epitope-independent structural feature by which the subtype
C V3 crown resists neutralization by a variety of anti-V3
antibodies appears to be a rigid N-terminal non-β-strand
conformation at positions 12 to 14 of the V3 loop. This eﬀect
is exclusive of the more commonly observed mechanism
of antibody escape, that is, mutations of key neutralization
epitope side chains, such as R18Q for 447-52D which we
have shown results in a distinguishable, antibody-speciﬁc
resistance. The combination of the loss of key neutralization
epitope amino acid side chains with rigidity or non-β-
strand structure results in total resistance of the psV bearingAdvances in Virology 5
Table 2: IC50s (ug/mL) of 15 diﬀerent antibodies (columns) derived from subtype B and subtype A infected patients neutralizing the
infectivity of psVs containing the subtype C and B V3 sequences in the SF162 Env backbone. For comparison, the IC50 values for a non-
V3 Ab (b12) are as follows: clade B cons. (JR-FL) = 0.009ug/mL; clade C cons. = 0.02ug/mL, all others untested; which does not show as
dramatic a diﬀerence in neutralization between the two psVs. 135 MPL23a is a subtype C primary isolate and is included as an example
of IC50 values in non-neutralization-sensitive (“masked”) backgrounds. IC50 values are font-type coded as follows: bold >0.1ug/mL; italic
<0.1ug/mL; bold/italic <0.01ug/mL.
V3 sequence
Anti-V3 mAbs from clade B infected patients Anti-V3 mAbs from clade A infected patients
2412 4117 2442 4148 2456 447 2191 2219 2128 3074 2557 2558 3019 3224 2601
c1. B cons
(JR-FL) 0.0009 0.0055 0.0018 0.0053 0.0039 0.00054 0.0023 0.0012 0.0013 0.0055 0.0037 0.0049 0.0027 0.0051 0.12
clade A1 cons 2.81 14.4 0.027 0.068 0.083 0.58 0.043 0.029 >20 0.015 0.025 0.038 0.032 0.044 0.029
clade C cons >20 >20 >20 2.5 0.44 >20 0.59 0.15 >20 0.2 0.16 0.2 0.25 1.8 0.17
IC50ratios
B/C >22,000 >3,600 >11,000 470 113 >37,000 257 125 >15,000 36 43 41 93 345 1.4
135 MPI
23a∗ >20 >20 >20 >20 >20 >20 >20 >20 >20 8.0 >20 77.0 93.0 >20 >20
∗Primary subtype C isolate.
these V3 loop properties to neutralization by the antibody
in question. Since these are intrinsic features of the V3
loop sequences, this phenomenon would apply to circulating
viruses bearing these properties in their V3 loops as well,
speciﬁcally subtype C viruses. Our dissection of the eﬀects
of single V3 loop point mutations shows that the eﬀects of
each point mutation is complex, and the backbone eﬀect is
combinatorial to all of the V3 loop positions simultaneously.
Thus, no single amino acid position is solely responsible for
the conC structural phenomenon. The convergence of three
completely independent sets of data—(1) known crystallo-
graphic structures of V3 peptides bound to antibody, (2)
patterns of psV neutralization, and (3) validated ab initio
folding simulations—strongly supports these conclusions.
Our observation suggests that a ﬂexible, β-strand
structure at positions 12 to 14 is required for anti-V3
antibody-mediated neutralization, and indeed this region is
bound by many anti-V3 antibodies. Nevertheless, it cannot
be concluded that antibody binding alone underlies this
structure-activity relationship. Neutralization is a multistep
process with antibody binding being only one step. One
can imagine a rigid V3 loop crown shape that is perfectly
complementary to an antibody-combining site and therefore
binds the antibody in vitro, but the virus may nevertheless
be neutralization resistant due to the eﬀects of this selfsame
rigidity at other steps in the neutralization process. For
example, neutralization-relevant V3 loop interactions with
severalothersurfacesofgp120maybeaﬀectedbytherigidity
in the V3 loop crown. For this reason, it is possible that
structural rigidity in the V3 loop crown may also inﬂuence
neutralization by non-V3-targeted antibodies by inhibiting
intermediate conformations involving the V3 loop in the
series of conformational changes that likely comprise the
overall neutralization process. Indeed, the conC psV exhibits
mildly increased resistance to the non-V3 Ab b12 (Table 2).
The unique resistance of conC to a wide variety of
subtype A and subtype B derived anti-V3 antibodies may
be informed by the observation of low variability of the
consensus C sequence in circulating subtype C strains [26].
If neutralization via the V3 loop is a strong selection
pressure on circulating subtype C viruses, then infective
V3 loop sequences harboring resistance to anti-V3-loop-
antibody mediated neutralization might be observed at a
higher rate and exhibit fewer escape mutations (vary less
in sequence). As a corollary, subtype A and B derived anti-
V3 antibodies may not be very eﬀective as vaccine tools
to combat subtype C, an observation that has previously
been suggested for subtype B [27]. Diﬀerent strategies for
interrogation of subtype C infected HIV+ sera may be
required to uncover novel, eﬀective neutralizing antibody
responses to this subtype. On the other hand, a diversity of
V3 loop sequences are present in subtype C in addition to
the dominant conC and conC-like sequences. It is unlikely
that the eﬀe c tw eh a v eo b s e r v e di su n i v e r s a li ns u b t y p eC ,
and some subtype C strains may exhibit V3 loop ﬂexibility
or encode compensatory changes in other parts of gp120 to
aﬀord eﬃcient neutralization by anti-V3 antibodies.
The psV neutralization data correlates strongly with the
results of the folding simulations. This correlation extends
previous observations suggesting that the 12 β-hairpin
residues (positions 10 to 22) of the V3 crown—including
the currently known anti-V3 antibody combining sites—
are suﬃciently ﬂexible in situ in the V3 loop to behave
essentially as free peptides or as an autonomously folded
subdomain [18–20]. Ab initio folding simulations of the V3
loop crown may therefore visualize at low resolution the
dynamic structural ensemble of some V3 loop crowns in
silico, a potentially important high-throughput capability for
mapping structure-(neutralization) activity relationships in
the V3 loop crown. It should be noted that the identiﬁcation
of two properties that are more easily assessed in a dynamic
ensemble of many conformations—secondary structure and
rigidity—facilitated the comparative interpretation of our
library of folding data. Observing the structural tendency at
a very speciﬁc location—positions 12 to 14 in the V3 loop—
also facilitated the study. More subtle and global struc-
turalpatterns,includingoverallfoldassignmentandabsolute
energetic stability for the whole domain, may be more6 Advances in Virology
diﬃcult to discern and assess across diﬀerent foldings for the
purpose of correlations with experiments.
The strong correlation of the psV neutralization mea-
surements with observed structural features in the folding
simulationsalsoestablishestheSF162chimericpsVsystemas
one that provides, even to ﬁne resolution, a consistent viro-
logic background across multiple experiments and V3 loop
sequence variations. The combination of chimeric psV neu-
tralization measurements with ab initio folding simulations
allowsdetailedquantitativedynamic structure-neutralization
activity relationships to be mapped out for the V3 loop. Such
studies would be diﬃcult with crystallography, which is low
throughput and does not evaluate dynamic structure.
Antibody epitopes in the V3 loop may occur broadly
in HIV-1 viruses, but antibodies appear to be limited
in accessing these epitopes presumably due to the eﬀects
of “masking” glycans and nearby variable domains [17].
In this work, the comparison of neutralization tests with
folding simulations may have revealed an obscure structural
explanation for epitope-independent variations in antibody-
mediated neutralization. The fact that some of the resistance
to antibody-mediated neutralization maps directly to the
antibody binding area of the V3 loop inﬂuences the view of
masking: some of the observed masking of V3 loop epitopes
may be intrinsic to the V3 loop itself and not due to outside
factors such as glycans and the other variable loops of gp120,
although both factors are likely operative to diﬀerent degrees
in any given strain. The approach described here could
potentially be modiﬁed to “localize” the masking of the V3
loop epitope in primary HIV-1 isolates, at least to V3 loop
or “outside-V3 loop” locations, by identifying anti-V3 loop
antibody-resistant primary isolate sequences in which this
“local masking” is present.
HIV-1 strains that evolve to partially mask receptor
interactingsurfacesinordertohidethosevulnerablesurfaces
from the immune system trade a loss of infective eﬃciency
for a gain in camouﬂage protection. The coincidence of
determinants for infection (chemokine receptor binding sur-
faces) and immune detection (broadly neutralizing epitopes)
in the V3 loop likely requires such a tradeoﬀ for best viral
ﬁtness. Since a wide variety of anti-V3 antibodies appear
to adhere to the antibody resistance mechanism described
here, the work suggests that this tradeoﬀ is accomplished in
subtypeCpartlybytheadoptionofV3loopstructuralshapes
that are ineﬃcient for both antibody-mediated neutraliza-
tion and coreceptor binding, that is, rigid non-β-strand
conformations. As the same viral mechanisms that produce
this feature of the V3 loop beget the structural features of the
other four variable loops, it is likely that the same tradeoﬀ
is exploited by viral evolution for functional regions of the
V1/V2, V4, and V5-loops. If anti-variable loop antibodies
play a signiﬁcant enough role in the human protective
response to circulating HIV-1 strains, the phenomenon we
have described here may explain the concurrent diverging
observations of decreased ﬁtness (poorer receptor usage)
and increased natural spread (successful immune evasion)
in subtype C. Indeed, the recent identiﬁcation of anti-V2
loop Abs as the only known inverse correlate of risk for HIV
infection suggests that antibodies to variable loops indeed
play a signiﬁcant role in the human protective response from
circulating HIV-1 strains [28].
4. Methods
4.1.DynamicStructuralCharacterizationoftheV3Crown. In
order to eﬃciently correlate 3D structure with neutralization
patterns, the visualization of the dynamic conformational
landscape of various mutants of the V3 loop crown in silico
is needed. Interestingly, the identical sequence—V3MN—has
been solved in complex with the two diﬀerent antibodies
and adopts diﬀerent β-strand structures in the two diﬀerent
environments despite the identical sequence. These essen-
tially represent biologically relevant snapshots of two con-
formations out of many in V3MN’s dynamic conformational
ensemble. We previously reported that a state-of-the-art Ab
initio peptide folding algorithm could accurately reveal the
conformational landscape and dynamic tertiary structure of
the V3 loop crown by analyzing whether the two diﬀerent
forms of V3MN seen in the crystallographic structures were
recapitulated [18]. ab initio folding of residues 10 to 22 of
the V3 crown recapitulated the two forms and demonstrated
the relationship between them (the 2219 form is the lower
energymoreprevalentform).Sincetheinputtothefoldingis
onlytheaminoacidsequence,thisalgorithmcanthusatleast
faintly visualize in silico the biologically relevant dynamic
ensemble of any V3 loop crown sequence from position 10
to 22. This capability was later veriﬁed by an independent
group [19]. This result also suggests that this portion of the
V3 crown behaves similarly to an autonomously folded, free,
unconstrained peptide, since the folding simulation used no
constraints on the two stems of the peptide and the folding
qualitatively recapitulated a form seen experimentally in the
V3loopinsituingp120[6].Finally,thistechnologywasused
to engineer an α-helical V3 loop crown and demonstrate
that it loses infectivity [20]. Ab initio folding of residues 10
to 22 of the V3 crown of all the psVs used in this study
was thus used to evaluate the ﬂexibility and conformational
preferences of V3 loop crown structures in silico.
All folding simulations and analysis were performedwith
ICMsoftware(MolSoftLLC,LaJolla,CA,USA)aspreviously
described [21]. This algorithm has previously been shown to
predict experimentally veriﬁed peptide structures up to 23
residues in length within the error accuracy limit [22]. As
a starting point for each folding run, fully extended confor-
mations of full-atom (including hydrogens) models of each
indicated V3 loop crown sequence (positions 10–22) were
generated.Thetotalnumberofenergyevaluationsduringthe
MC run was based on the number of free variables (number
offreestandardtorsionangles).EachMCruntook2-3hours
o fC P Ut i m eo na3 . 0 0G h zD u a l - C o r eI n t e lX e o nP r o c e s s o r .
The exact script for the foldings and all the folding data are
available upon request from the corresponding author.
All the data on chimeric psV construction and neu-
tralization assays were previously reported in the literature
[14, 17], except those repeated for conﬁrmation in this study
or those in Table 2. In all cases, the same method was used.
Brieﬂy, each chimeric psV was constructed to contain a
diﬀerent V3 loop sequence grafted in to replace the V3 loopAdvances in Virology 7
in the SF162 Env, where the V3 loop is relatively accessible
(“unmasked”) [17]. Thus, the observed diﬀerences in psV
neutralization elicited by each mAb maps to diﬀerences in
the V3 loop sequences. The V3 chimeric SF162 psVs were
constructed with V3 mutations introduced as indicated in
the text in the consensus subtype B or consensus subtype C
V3 loop, or V3 chimeric SF162 psVs were constructed in
which the SF162 V3 loop was replaced with the V3 loop
consensus sequences from subtypes A1, B, C. The neutraliza-
tion by mAbs 447-52D and 2219, as well as other Abs, of
each of these psVs was assessed using methods previously
described [23]. Brieﬂy, neutralizing activity was determined
withasingle-cycleinfectivityassayusingpsVsgeneratedwith
the env-defective luciferase-expressing pNL4-3.Luc.R-E-
plasmid v [24] pseudotyped with the SF162 V3 variants de-
scribed above. The psVs were incubated with serial dilu-
t i o n so fm A b sf o r1 . 5h o u ra t3 7 ◦C and then added to
CD4+CCR5+U87 target cells plated in 96-well plates in the
presence of polybrene (10mg/mL). After 24hrs, cells were
refedwithRPMImediumcontaining10%FBSand10μg/mL
polybrene, followed by an additional 24–48hr incubation.
Luciferase activity was determined 48–72hrs postinfection
with a microtiter plate luminometer (HARTA, Inc.) using
assay reagents from Promega, Inc. Geometric mean titers for
50% neutralization (GMT50) were determined by interpola-
tion from neutralization curves and are averages of at least
three independent assays.
Abbreviations
HIV: Human immunodeﬁciency virus.
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